Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vector Type, By Delivery Method, By Indication, By Region & Competition, 2020-2030F

Description

Global Gene Therapy Market was valued at USD 6.54 Billion in 2024 and is expected to reach USD 11.29 Billion by 2030 with a CAGR of 9.53% during the forecast period. The gene therapy is described as the treatment of an illness by changing, replacing, or supplementing a missing or defective genetic combination that is responsible for the disease. The gene therapy has become one of the most desirable research goals in the fight against degenerative illnesses. The need for gene therapy is being driven by an increase in the number of cases of cancer and other chronic diseases all across the world. The advancements in gene therapies are projected to be approved in the upcoming years, contributing to the gene therapy market's growth during the forecast period. The gene therapies are designed to treat diseases by altering genetic information, such as inactivating malfunctioning genes or replacing a disease-causing gene with a healthy copy of gene. The gene therapy is being utilized to treat a variety of disorders and has demonstrated to be effective. This form of treatment can cure diseases such as diabetes, cancer, heart disease, and AIDS.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 6.54 Billion
Market Size 2030	USD 11.29 Billion
CAGR 2025-2030	9.53%
Fastest Growing Segment	Non-viral vectors
Largest Market	North America

The strong pipeline of gene therapy products is anticipated to drive market growth over the forecast period. Researchers are actively working to make gene therapy more accessible in clinical settings. Numerous universities and research institutes are developing a diverse range of gene therapy products, which is expected to contribute significantly to revenue generation in the coming years. The number of clinical trials for gene therapy saw a notable increase between 2017 and 2018, following the FDA's approval of the first gene therapy. According to the American Society of Gene & Cell Therapy (ASGCT), approximately 1,986 gene therapy products, including CAR T-cell therapies and other genetically modified cell treatments, are currently in development, further accelerating market expansion.

Key Market Drivers

Advancements in Genetic Research

The increasing understanding of the genetic basis of diseases has enabled scientists to identify specific genes responsible for various disorders. This knowledge is crucial for designing targeted gene therapies that can correct or replace defective genes, addressing the root cause of diseases. Genetic research has identified specific genetic mutations or abnormalities that contribute to various diseases, such as inherited genetic disorders and certain types of cancer. This has provided gene therapists with clear therapeutic targets, allowing them to develop more precise and effective treatments. Advancements in gene editing technologies, such as CRISPR-Cas9, TALENs, and zinc finger nucleases, have revolutionized gene therapy. These techniques enable scientists to accurately and efficiently edit or modify genes, opening up new possibilities for treating genetic disorders. Genetic research has paved the way for personalized medicine, where treatments are tailored to an individual's genetic makeup. This approach enhances the effectiveness of gene therapies by considering genetic variations that might affect treatment outcomes, leading to better patient responses and reduced adverse effects. Genetic research has facilitated the development of advanced delivery systems that help target specific tissues or cells with greater precision. This has improved the efficiency of gene therapy treatments, minimized off-target effects and enhancing therapeutic outcomes. The promising outcomes of genetic research have attracted substantial investment in the gene therapy sector. As the potential of gene therapies becomes more apparent, investors are more willing to fund research and development, driving innovation and market growth. For example, in December 2023, the U.S. FDA approved a gene therapy for sickle cell disease, marking the first-ever gene therapy based on CRISPR gene editing. Such groundbreaking advancements and product launches are expected to drive market growth over the forecast period.

Key Market Challenges

Technical Complexity

Developing effective gene therapies requires a deep understanding of genetics, molecular biology, and complex cellular processes. The technical complexity of designing therapies that accurately target and modify specific genes can lead to prolonged research and development timelines. Getting therapeutic genes into target cells poses a significant challenge. Developing efficient and safe delivery systems, such as viral vectors or nanoparticles, requires extensive optimization and testing. Technical difficulties in achieving precise and controlled delivery can affect the success of gene therapies. The interactions between modified genes and the host organism can sometimes lead to unintended consequences. Technical complexities can make it difficult to predict the outcomes of gene therapies accurately, leading to safety concerns and regulatory challenges. Regulatory agencies require a high level of safety and efficacy data for gene therapy products due to their complexity and potential risks. Navigating the regulatory pathway for gene therapies can be challenging and time-consuming, hindering market growth. Manufacturing gene therapy products in a consistent and scalable manner is challenging due to the complexity of biological processes involved. Ensuring the quality, safety, and stability of gene therapies at a commercial scale can be technically demanding and expensive.

Key Market Trends

Expanding Therapeutic Targets

Identifying new therapeutic targets means gene therapy can be applied to a wider range of medical conditions beyond traditional monogenic disorders. This diversity includes complex diseases like cancer, cardiovascular diseases, neurodegenerative disorders, and rare diseases, expanding the addressable patient population. The availability of gene therapies for multiple therapeutic targets attracts a larger patient base, driving market growth by increasing the potential customer pool and commercial opportunities. The discovery of new therapeutic targets stimulates research and development efforts by both established pharmaceutical companies and smaller biotechnology firms. This influx of investment fuels innovation and accelerates the development of gene therapies for various indications. Expanding therapeutic targets leads to a more diverse portfolio of clinical trials. This diversity enhances the clinical trial landscape, allowing researchers to explore different patient populations, endpoints, and treatment approaches, ultimately advancing the field. As gene therapies target a wider array of diseases, regulatory agencies may provide specialized pathways or guidelines for specific indications. This attention can expedite regulatory approval processes and facilitate market entry. The availability of gene therapies for more common and relatable diseases can increase public awareness and acceptance of the technology. Positive outcomes in well-known conditions can build trust and reduce skepticism. Expanding therapeutic targets can lead to collaborations between academic researchers, industry partners, and patient advocacy groups. Collaborations strengthen expertise, resources, and support networks, fostering innovation and growth. The potential for gene therapies to target various indications attracts diverse investors interested in contributing to the development of treatments for specific diseases, fostering a competitive market landscape.

Key Market Players

REGENXBIO Inc.
Oxford Biomedica PLC.
Voyager Therapeutics Inc.
Human Stem Cells Institute
Dimension Therapeutics, Inc.
Bristol-Myers Squibb Company
Sanofi
F. Hoffmann-La Roche Ltd
bluebird bio, Inc.
Novartis AG
uniQure NV.

Report Scope:

In this report, the Global Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Therapy Market, By Vector Type:

Viral Vector
Non-Viral Vector

Gene Therapy Market, By Delivery Method:

In-Vivo
Ex-Vivo

Gene Therapy Market, By Indication:

Rare Diseases
Cancer
Neurological Diseases
Others

Gene Therapy Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Therapy Market.

Available Customizations:

Global Gene Therapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

4.1 Ongoing Clinical Trials

4.2 Completed Clinical Trials

4.3 Terminated Clinical Trials

4.4 Breakdown of Pipeline, By Development Phase

4.5 Breakdown of Pipeline, By Status

4.6 Breakdown of Pipeline, By Study Type

4.7 Breakdown of Pipeline, By Region

4.8 Clinical Trials Heat Map

5. Voice of Customer

6. Global Gene Therapy Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
- 6.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
- 6.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
- 6.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
- 6.2.5. By Company (2024)
6.3. Market Map
6.3.1 By Vector Type
6.3.2 By Delivery Method
6.3.3 By Indication
6.3.4 By Region

7. North America Gene Therapy Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
- 7.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
- 7.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
- 7.2.4. By Country
7.3. North America: Country Analysis
- 7.3.1. United States Gene Therapy Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Vector Type
    - 7.3.1.2.2. By Delivery Method
    - 7.3.1.2.3. By Indication
- 7.3.2. Canada Gene Therapy Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Vector Type
    - 7.3.2.2.2. By Delivery Method
    - 7.3.2.2.3. By Indication
- 7.3.3. Mexico Gene Therapy Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Vector Type
    - 7.3.3.2.2. By Delivery Method
    - 7.3.3.2.3. By Indication

8. Europe Gene Therapy Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
- 8.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
- 8.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
- 8.2.4. By Country
8.3. Europe: Country Analysis
- 8.3.1. France Gene Therapy Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Vector Type
    - 8.3.1.2.2. By Delivery Method
    - 8.3.1.2.3. By Indication
- 8.3.2. Germany Gene Therapy Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Vector Type
    - 8.3.2.2.2. By Delivery Method
    - 8.3.2.2.3. By Indication
- 8.3.3. United Kingdom Gene Therapy Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Vector Type
    - 8.3.3.2.2. By Delivery Method
    - 8.3.3.2.3. By Indication
- 8.3.4. Italy Gene Therapy Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Vector Type
    - 8.3.4.2.2. By Delivery Method
    - 8.3.4.2.3. By Indication
- 8.3.5. Spain Gene Therapy Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Vector Type
    - 8.3.5.2.2. By Delivery Method
    - 8.3.5.2.3. By Indication

9. Asia-Pacific Gene Therapy Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
- 9.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
- 9.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
- 9.2.4. By Country
9.3. Asia-Pacific: Country Analysis
- 9.3.1. China Gene Therapy Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Vector Type
    - 9.3.1.2.2. By Delivery Method
    - 9.3.1.2.3. By Indication
- 9.3.2. India Gene Therapy Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Vector Type
    - 9.3.2.2.2. By Delivery Method
    - 9.3.2.2.3. By Indication
- 9.3.3. Japan Gene Therapy Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Vector Type
    - 9.3.3.2.2. By Delivery Method
    - 9.3.3.2.3. By Indication
- 9.3.4. South Korea Gene Therapy Market Outlook
  - 9.3.4.1. Market Size & Forecast
    - 9.3.4.1.1. By Value
  - 9.3.4.2. Market Share & Forecast
    - 9.3.4.2.1. By Vector Type
    - 9.3.4.2.2. By Delivery Method
    - 9.3.4.2.3. By Indication
- 9.3.5. Australia Gene Therapy Market Outlook
  - 9.3.5.1. Market Size & Forecast
    - 9.3.5.1.1. By Value
  - 9.3.5.2. Market Share & Forecast
    - 9.3.5.2.1. By Vector Type
    - 9.3.5.2.2. By Delivery Method
    - 9.3.5.2.3. By Indication

10. South America Gene Therapy Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
- 10.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
- 10.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Gene Therapy Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Vector Type
    - 10.3.1.2.2. By Delivery Method
    - 10.3.1.2.3. By Indication
- 10.3.2. Argentina Gene Therapy Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Vector Type
    - 10.3.2.2.2. By Delivery Method
    - 10.3.2.2.3. By Indication
- 10.3.3. Colombia Gene Therapy Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Vector Type
    - 10.3.3.2.2. By Delivery Method
    - 10.3.3.2.3. By Indication

11. Middle East and Africa Gene Therapy Market Outlook

11.1. Market Size & Forecast
- 11.1.1. By Value
11.2. Market Share & Forecast
- 11.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
- 11.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
- 11.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
- 11.2.4. By Country
11.3. MEA: Country Analysis
- 11.3.1. South Africa Gene Therapy Market Outlook
  - 11.3.1.1. Market Size & Forecast
    - 11.3.1.1.1. By Value
  - 11.3.1.2. Market Share & Forecast
    - 11.3.1.2.1. By Vector Type
    - 11.3.1.2.2. By Delivery Method
    - 11.3.1.2.3. By Indication
- 11.3.2. Saudi Arabia Gene Therapy Market Outlook
  - 11.3.2.1. Market Size & Forecast
    - 11.3.2.1.1. By Value
  - 11.3.2.2. Market Share & Forecast
    - 11.3.2.2.1. By Vector Type
    - 11.3.2.2.2. By Delivery Method
    - 11.3.2.2.3. By Indication
- 11.3.3. UAE Gene Therapy Market Outlook
  - 11.3.3.1. Market Size & Forecast
    - 11.3.3.1.1. By Value
  - 11.3.3.2. Market Share & Forecast
    - 11.3.3.2.1. By Vector Type
    - 11.3.3.2.2. By Delivery Method
    - 11.3.3.2.3. By Indication

12. Market Dynamics

12.1. Drivers
12.2. Challenges

13. Market Trends & Developments

13.1. Recent Development
13.2. Mergers & Acquisitions
13.3. Product Launches

14. Global Gene Therapy Market: SWOT Analysis

15. Funding Analysis

16. Porter's Five Forces Analysis

16.1. Competition in the Industry
16.2. Potential of New Entrants
16.3. Power of Suppliers
16.4. Power of Customers
16.5. Threat of Substitute Products

17. Competitive Landscape

17.1. REGENXBIO Inc.
- 17.1.1. Business Overview
- 17.1.2. Company Snapshot
- 17.1.3. Products & Services
- 17.1.4. Financials (As Reported)
- 17.1.5. Recent Developments
- 17.1.6. Key Personnel Details
- 17.1.7. SWOT Analysis
17.2. Oxford Biomedica PLC.
17.3. Voyager Therapeutics Inc.
17.4. Human Stem Cells Institute
17.5. Dimension Therapeutics, Inc.
17.6. Bristol-Myers Squibb Company
17.7. Sanofi
17.8. F. Hoffmann-La Roche ltd.
17.9. bluebird bio, Inc.
17.10. Novartis AG
17.11. Uniqure N.V.